231 related articles for article (PubMed ID: 19801219)
1. Prostate cancer: role of SPECT and PET in imaging bone metastases.
Beheshti M; Langsteger W; Fogelman I
Semin Nucl Med; 2009 Nov; 39(6):396-407. PubMed ID: 19801219
[TBL] [Abstract][Full Text] [Related]
2. Miscellaneous cancers (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors): role of SPECT and PET in imaging bone metastases.
Chua S; Gnanasegaran G; Cook GJ
Semin Nucl Med; 2009 Nov; 39(6):416-30. PubMed ID: 19801221
[TBL] [Abstract][Full Text] [Related]
3. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I
J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635
[TBL] [Abstract][Full Text] [Related]
4. (18)F-fluoride positron emission tomography/computed tomography and bone scintigraphy for diagnosis of bone metastases in newly diagnosed, high-risk prostate cancer patients: study protocol for a multicentre, diagnostic test accuracy study.
Fonager RF; Zacho HD; Langkilde NC; Petersen LJ
BMC Cancer; 2016 Jan; 16():10. PubMed ID: 26753880
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer: role of SPECT and PET in imaging bone metastases.
Ben-Haim S; Israel O
Semin Nucl Med; 2009 Nov; 39(6):408-15. PubMed ID: 19801220
[TBL] [Abstract][Full Text] [Related]
6. Nuclear medicine studies of the prostate, testes, and bladder.
Jana S; Blaufox MD
Semin Nucl Med; 2006 Jan; 36(1):51-72. PubMed ID: 16356796
[TBL] [Abstract][Full Text] [Related]
7. Imaging of bone metastases in prostate cancer: an update.
Langsteger W; Haim S; Knauer M; Waldenberger P; Emmanuel K; Loidl W; Wolf I; Beheshti M
Q J Nucl Med Mol Imaging; 2012 Oct; 56(5):447-58. PubMed ID: 23069924
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography and bone metastases.
Fogelman I; Cook G; Israel O; Van der Wall H
Semin Nucl Med; 2005 Apr; 35(2):135-42. PubMed ID: 15765376
[TBL] [Abstract][Full Text] [Related]
9. [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].
García JR; Soler M; Blanch MA; Ramírez I; Riera E; Lozano P; Pérez X; Delgado E; Carrio I; Lomeña F
Rev Esp Med Nucl; 2009; 28(3):95-100. PubMed ID: 19558948
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Prostate Cancer Bone Metastases with 18F-NaF and 18F-Fluorocholine PET/CT.
Beheshti M; Rezaee A; Geinitz H; Loidl W; Pirich C; Langsteger W
J Nucl Med; 2016 Oct; 57(Suppl 3):55S-60S. PubMed ID: 27694173
[No Abstract] [Full Text] [Related]
11. PET Tracer
Oka S; Kanagawa M; Doi Y; Schuster DM; Goodman MM; Yoshimura H
Theranostics; 2017; 7(7):2048-2064. PubMed ID: 28656060
[No Abstract] [Full Text] [Related]
12. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management.
Hetzel M; Arslandemir C; König HH; Buck AK; Nüssle K; Glatting G; Gabelmann A; Hetzel J; Hombach V; Schirrmeister H
J Bone Miner Res; 2003 Dec; 18(12):2206-14. PubMed ID: 14672356
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET.
Schirrmeister H; Guhlmann A; Elsner K; Kotzerke J; Glatting G; Rentschler M; Neumaier B; Träger H; Nüssle K; Reske SN
J Nucl Med; 1999 Oct; 40(10):1623-9. PubMed ID: 10520701
[TBL] [Abstract][Full Text] [Related]
14. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis.
Evangelista L; Cimitan M; Zattoni F; Guttilla A; Zattoni F; Saladini G
Scand J Urol; 2015; 49(5):345-53. PubMed ID: 25649494
[TBL] [Abstract][Full Text] [Related]
15. C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy.
Yu EY; Muzi M; Hackenbracht JA; Rezvani BB; Link JM; Montgomery RB; Higano CS; Eary JF; Mankoff DA
Clin Nucl Med; 2011 Mar; 36(3):192-8. PubMed ID: 21285676
[TBL] [Abstract][Full Text] [Related]
16. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer.
Uematsu T; Yuen S; Yukisawa S; Aramaki T; Morimoto N; Endo M; Furukawa H; Uchida Y; Watanabe J
AJR Am J Roentgenol; 2005 Apr; 184(4):1266-73. PubMed ID: 15788608
[TBL] [Abstract][Full Text] [Related]
17. [(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer.
Tuncel M; Souvatzoglou M; Herrmann K; Stollfuss J; Schuster T; Weirich G; Wester HJ; Schwaiger M; Krause BJ
Nucl Med Biol; 2008 Aug; 35(6):689-95. PubMed ID: 18678354
[TBL] [Abstract][Full Text] [Related]
18. 18F-Fluoride positron emission tomography and positron emission tomography/computed tomography.
Even-Sapir E; Mishani E; Flusser G; Metser U
Semin Nucl Med; 2007 Nov; 37(6):462-9. PubMed ID: 17920353
[TBL] [Abstract][Full Text] [Related]
19. The roles of PET and PET/CT in the diagnosis and management of prostate cancer.
Takahashi N; Inoue T; Lee J; Yamaguchi T; Shizukuishi K
Oncology; 2007; 72(3-4):226-33. PubMed ID: 18176088
[TBL] [Abstract][Full Text] [Related]
20. Nuclear Medicine Imaging Techniques for Detection of Skeletal Metastases in Breast Cancer.
Iagaru A; Minamimoto R
PET Clin; 2018 Jul; 13(3):383-393. PubMed ID: 30100077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]